{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:40:03Z","timestamp":1793144403604,"version":"4.5.0"},"reference-count":268,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jacl.2013.08.001","type":"journal-article","created":{"date-parts":[[2013,8,11]],"date-time":"2013-08-11T03:15:18Z","timestamp":1376190918000},"page":"484-525","source":"Crossref","is-referenced-by-count":298,"title":["High-density lipoproteins: A consensus statement from the National Lipid Association"],"prefix":"10.1016","volume":"7","author":[{"given":"Peter P.","family":"Toth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Barter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Boden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. John","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Cuchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Sr.","given":"Ralph B.","family":"D'Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Sean","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay W.","family":"Heinecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Karas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatol","family":"Kontush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2013.08.001_bib1","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"issue":"suppl","key":"10.1016\/j.jacl.2013.08.001_bib2","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1194\/jlr.R800034-JLR200","article-title":"The metabolism and anti-atherogenic properties of HDL","volume":"50","author":"Rye","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature09270","article-title":"Biological, clinical and population relevance of 95 loci for blood lipids","volume":"466","author":"Teslovich","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jacl.2013.08.001_bib4","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1172\/JCI114558","article-title":"Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit","volume":"85","author":"Badimon","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2013.08.001_bib5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/353265a0","article-title":"Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI","volume":"353","author":"Rubin","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.jacl.2013.08.001_bib6","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/S0022-2275(20)39932-6","article-title":"Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice","volume":"35","author":"Liu","year":"1994","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib7","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1073\/pnas.91.20.9607","article-title":"Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse","volume":"91","author":"Plump","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2013.08.001_bib8","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib9","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib10","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib11","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib12","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/01.CIR.34.4.679","article-title":"Ischemic heart disease, atherosclerosis, and longevity","volume":"34","author":"Gofman","year":"1966","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0140-6736(75)92376-4","article-title":"Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease","volume":"1","author":"Miller","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2013.08.001_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM197602052940601","article-title":"Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men","volume":"294","author":"Rhoads","year":"1976","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"issue":"suppl 9","key":"10.1016\/j.jacl.2013.08.001_bib17","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/00005344-199006169-00004","article-title":"HDL metabolism and atherosclerosis","volume":"16","author":"Assmann","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacl.2013.08.001_bib18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/oxfordjournals.aje.a112683","article-title":"High density lipoprotein cholesterol and incidence of coronary heart disease\u2013the Israeli Ischemic Heart Disease Study","volume":"109","author":"Goldbourt","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.ATV.17.1.107","article-title":"Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men","volume":"17","author":"Goldbourt","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"suppl","key":"10.1016\/j.jacl.2013.08.001_bib20","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/0021-9150(96)05852-2","article-title":"High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport","volume":"124","author":"Assmann","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2013.08.001_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/oxfordjournals.aje.a112682","article-title":"The\u00a0association of low levels of HDL cholesterol and arteriographically defined coronary artery disease","volume":"109","author":"Pearson","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/oxfordjournals.epirev.a036269","article-title":"Coronary arteriography in the study of the epidemiology of coronary artery disease","volume":"6","author":"Pearson","year":"1984","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.jacl.2013.08.001_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archinte.1988.00380010040006","article-title":"Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel","volume":"148","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0002-9343(86)90157-9","article-title":"A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study","volume":"80","author":"Castelli","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/0002-9343(84)90952-5","article-title":"Epidemiology of coronary heart disease: the Framingham study","volume":"76","author":"Castelli","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.ATV.8.3.207","article-title":"High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study","volume":"8","author":"Abbott","year":"1988","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.jacl.2013.08.001_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9149(90)90017-U","article-title":"Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease","volume":"65","author":"Miller","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0002-9149(91)90742-4","article-title":"Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with \u201cdesirable\u201d total cholesterol levels","volume":"68","author":"Ginsburg","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib29","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/0002-9149(91)90924-A","article-title":"Prevalence of risk factors in men with premature coronary artery disease","volume":"67","author":"Genest","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0002-9149(91)90007-8","article-title":"Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease","volume":"67","author":"Romm","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib31","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/01.CIR.86.4.1165","article-title":"Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol","volume":"86","author":"Miller","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib32","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1161\/01.CIR.74.6.1217","article-title":"High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial","volume":"74","author":"Gordon","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib34","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib36","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib37","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/01.CIR.99.6.736","article-title":"Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy","volume":"99","author":"Ballantyne","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacl.2007.02.004","article-title":"Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence","volume":"1","author":"Brown","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2013.08.001_bib39","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jama.269.4.505","article-title":"NIH Consensus conference. Triglyceride, high-density lipoprotein, and coronary heart disease. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease","volume":"269","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib40","doi-asserted-by":"crossref","first-page":"9B","DOI":"10.1016\/0002-9149(83)90649-5","article-title":"High-density lipoproteins: epidemiologic profile and risks of coronary artery disease","volume":"52","author":"Kannel","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib41","series-title":"Advances in Internal Medicine","first-page":"39","article-title":"Comparison of risk profiles for cardiovascular events: implications for prevention","author":"Kannel","year":"1996"},{"key":"10.1016\/j.jacl.2013.08.001_bib42","first-page":"56","article-title":"Hypercholesterolemia and coronary risk in\u00a0the elderly: The Framingham Study","volume":"2","author":"Wilson","year":"1993","journal-title":"Am J Geriatr Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib43","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jama.1995.03530070037026","article-title":"HDL cholesterol predicts coronary heart disease mortality in older persons","volume":"274","author":"Corti","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib44","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0002-8703(92)90288-7","article-title":"Efficacy of lipid profiles in prediction of coronary disease","volume":"124","author":"Kannel","year":"1992","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2013.08.001_bib45","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib46","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/sim.1742","article-title":"Presentation of multivariate data for clinical use: the Framingham Study risk score functions","volume":"23","author":"Sullivan","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib47","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib48","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1001\/jama.1993.03500230091035","article-title":"Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel","volume":"269","author":"Sempos","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib49","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/0026-0495(75)90063-3","article-title":"Familial hyper-alpha-lipoproteinemia: studies in eighteen kindreds","volume":"24","author":"Glueck","year":"1975","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2013.08.001_bib50","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJM199011013231803","article-title":"Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation","volume":"323","author":"Inazu","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib51","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.ATV.17.6.1053","article-title":"Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity","volume":"17","author":"Hirano","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib52","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00109-002-0407-6","article-title":"Deficiency of cholesteryl ester transfer protein and gene polymorphisms of lipoprotein lipase and hepatic lipase are not associated with longevity","volume":"81","author":"Arai","year":"2003","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.jacl.2013.08.001_bib53","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/gerona\/63.11.1235","article-title":"A prospective study of high-density lipoprotein cholesterol, cholesteryl ester transfer protein gene variants, and healthy aging in very old Japanese-American men","volume":"63","author":"Koropatnick","year":"2008","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jacl.2013.08.001_bib54","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-006-0070-4","article-title":"The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease","volume":"84","author":"Rhyne","year":"2006","journal-title":"J Mol Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib55","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa0907687","article-title":"Genetic variant of the scavenger receptor BI in humans","volume":"364","author":"Vergeer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib56","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2013.08.001_bib57","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jacl.2010.08.005","article-title":"The protein cargo of HDL: implications for vascular wall biology and therapeutics","volume":"4","author":"Heinecke","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2013.08.001_bib58","series-title":"Clinical Lipidology: A Companion to Braunwald's Heart Disease","author":"Ballantyne","year":"2009"},{"key":"10.1016\/j.jacl.2013.08.001_bib59","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0021-9150(03)00152-7","article-title":"Factors influencing coronary risk in low HDL syndromes","volume":"169","author":"Miller","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2013.08.001_bib60","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/01.ATV.11.1.174","article-title":"High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients","volume":"11","author":"Johansson","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.jacl.2013.08.001_bib61","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1194\/jlr.R200004-JLR200","article-title":"Metabolic origins and clinical significance of LDL heterogeneity","volume":"43","author":"Berneis","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib62","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI103182","article-title":"The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum","volume":"34","author":"Havel","year":"1955","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2013.08.001_bib63","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0021-9150(78)90005-9","article-title":"High density lipoprotein distribution. Resolution and determination of three major components in a normal population sample","volume":"29","author":"Anderson","year":"1978","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2013.08.001_bib64","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2010.10.024","article-title":"Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort","volume":"214","author":"Williams","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2013.08.001_bib65","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/0005-2760(81)90253-8","article-title":"Characterization of human high-density lipoproteins by gradient gel electrophoresis","volume":"665","author":"Blanche","year":"1981","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacl.2013.08.001_bib66","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1161\/01.ATV.0000146325.93749.a8","article-title":"High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study","volume":"24","author":"Asztalos","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib67","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-2275(20)35376-1","article-title":"A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum","volume":"22","author":"Chapman","year":"1981","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib68","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0022-2275(20)38096-2","article-title":"Computerized rapid high resolution quantitative analysis of plasma lipoproteins based upon single vertical spin centrifugation","volume":"23","author":"Cone","year":"1982","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib69","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0022-2275(20)34949-X","article-title":"Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology","volume":"38","author":"Kulkarni","year":"1997","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib70","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.cll.2006.07.004","article-title":"Cholesterol profile measurement by vertical auto profile method","volume":"26","author":"Kulkarni","year":"2006","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib71","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0005-2760(93)90253-6","article-title":"Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations","volume":"1169","author":"Asztalos","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacl.2013.08.001_bib72","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1194\/jlr.M500187-JLR200","article-title":"Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux","volume":"46","author":"Asztalos","year":"2005","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib73","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1161\/CIRCULATIONAHA.111.066589","article-title":"Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport","volume":"125","author":"Rosenson","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib74","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/01.ATV.0000183727.90611.4f","article-title":"Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial","volume":"25","author":"Asztalos","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib75","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.ATV.0000066133.32063.BB","article-title":"Change in alpha1 HDL concentration predicts progression in coronary artery stenosis","volume":"23","author":"Asztalos","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib76","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1103\/PhysRevLett.72.4049","article-title":"Effects of orientational order and particle size on the NMR line positions of lipoproteins","volume":"72","author":"Lounila","year":"1994","journal-title":"Phys Rev Lett"},{"key":"10.1016\/j.jacl.2013.08.001_bib77","first-page":"171","article-title":"Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy","volume":"48","author":"Otvos","year":"2002","journal-title":"Clin Lab"},{"key":"10.1016\/j.jacl.2013.08.001_bib78","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cll.2006.07.006","article-title":"Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy","volume":"26","author":"Jeyarajah","year":"2006","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib79","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0076-6879(86)29061-8","article-title":"Separation and analysis of lipoproteins by gel filtration","volume":"129","author":"Rudel","year":"1986","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.jacl.2013.08.001_bib80","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0022-2275(20)39346-9","article-title":"Characterization of subfractions of triglyceride-rich lipoproteins separated by gel chromatography from blood plasma of normolipemic and hyperlipemic humans","volume":"13","author":"Sata","year":"1972","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib81","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/0003-4819-150-2-200901200-00006","article-title":"High-density lipoprotein particle size and concentration and coronary risk","volume":"150","author":"El Harchaoui","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib82","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.108.816181","article-title":"Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women","volume":"119","author":"Mora","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib83","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1373\/clinchem.2007.100586","article-title":"Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis","volume":"54","author":"Caulfield","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2013.08.001_bib84","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1161\/ATVBAHA.109.190405","article-title":"Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk","volume":"29","author":"Musunuru","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib85","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11883-003-0036-8","article-title":"The concept of apolipoprotein-defined lipoprotein families and its clinical significance","volume":"5","author":"Alaupovic","year":"2003","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2013.08.001_bib86","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/S0022-2275(20)38408-X","article-title":"Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma","volume":"29","author":"James","year":"1988","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib87","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1373\/clinchem.2010.155333","article-title":"HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events","volume":"57","author":"Rosenson","year":"2011","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2013.08.001_bib88","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1161\/01.ATV.0000184760.95957.d6","article-title":"Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits","volume":"25","author":"Nicholls","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib89","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1074\/jbc.273.9.5033","article-title":"Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits","volume":"273","author":"Sugano","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2013.08.001_bib90","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/01.ATV.20.9.2106","article-title":"Vaccine-induced antibodies inhibit CETP activity in\u00a0vivo and reduce aortic lesions in a rabbit model of atherosclerosis","volume":"20","author":"Rittershaus","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib91","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35018119","article-title":"A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits","volume":"406","author":"Okamoto","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jacl.2013.08.001_bib92","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1194\/jlr.M600332-JLR200","article-title":"Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits","volume":"48","author":"Morehouse","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib93","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib94","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2013.08.001_bib95","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2013.08.001_bib96","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib97","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0002-9149(99)80761-9","article-title":"Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group","volume":"75","author":"Rubins","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib98","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/0735-1097(92)90520-W","article-title":"Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease","volume":"19","author":"Genest","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib99","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1172\/JCI30163","article-title":"Molecular regulation of HDL metabolism and function: implications for novel therapies","volume":"116","author":"Rader","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2013.08.001_bib100","first-page":"307","article-title":"Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies","volume":"20","author":"Meyers","year":"2005","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib101","first-page":"13","article-title":"Syndrome X: 6 years later","volume":"736","author":"Reaven","year":"1994","journal-title":"J Intern Med Suppl"},{"key":"10.1016\/j.jacl.2013.08.001_bib102","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","article-title":"Heart disease and stroke statistics\u20132011 update: a report from the American Heart Association","volume":"123","author":"Roger","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib103","first-page":"1","article-title":"Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006","volume":"13","author":"Ervin","year":"2009","journal-title":"Natl Health Stat Rep"},{"key":"10.1016\/j.jacl.2013.08.001_bib104","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1161\/CIRCULATIONAHA.105.548206","article-title":"Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age","volume":"113","author":"Lloyd-Jones","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib105","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jama.298.7.786","article-title":"High-density lipoprotein as a therapeutic target: a systematic review","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib106","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib107","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2013.08.001_bib108","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib109","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2013.08.001_bib110","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMc1006407","article-title":"Combination lipid therapy in type 2 diabetes","volume":"363","author":"Sacks","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib111","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib112","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib113","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.jacl.2013.08.001_bib114","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib115","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1001\/jama.1990.03450230049028","article-title":"Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up","volume":"264","author":"Cashin-Hemphill","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib116","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"issue":"suppl I","key":"10.1016\/j.jacl.2013.08.001_bib117","first-page":"I-635","article-title":"Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year familial atherosclerosis treatment study (FATS) follow-up [Abstract 3341]","volume":"98","author":"Brown","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib118","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib119","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib120","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2013.08.001_bib121","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib122","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1016\/j.jacc.2010.03.017","article-title":"The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration","volume":"55","author":"Villines","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib123","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.jacc.2009.06.036","article-title":"Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study","volume":"54","author":"Lee","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"suppl A","key":"10.1016\/j.jacl.2013.08.001_bib124","first-page":"262A","article-title":"Niacin plus simvastatin protect against atherosclerosis progression and clinical events in CAD patients with low HDL-C and diabetes mellitus or impaired fasting glucose","volume":"37","author":"Morse","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib125","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjcard.2004.09.013","article-title":"Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)","volume":"95","author":"Canner","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib126","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.amjcard.2005.08.070","article-title":"Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)","volume":"97","author":"Canner","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib127","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ahj.2010.11.017","volume":"161","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2013.08.001_bib128","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2013.08.001_bib129","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1172\/JCI59262","article-title":"Niacin and biosynthesis of PGD(2)by platelet COX-1 in mice and humans","volume":"122","author":"Song","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2013.08.001_bib130","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/eurheartj\/eht064","article-title":"The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin","volume":"34","author":"Landmesser","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2013.08.001_bib131","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jacc.2012.10.030","article-title":"The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression","volume":"61","author":"Lavigne","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib132","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1001\/jama.299.23.2777","article-title":"Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk","volume":"299","author":"Thompson","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib133","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCGENETICS.108.817304","article-title":"Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18245 initially healthy women from the Women's Genome Health Study","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacl.2013.08.001_bib134","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/ATVBAHA.106.138347","article-title":"Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL","volume":"27","author":"Yvan-Charvet","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib135","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1161\/CIRCULATIONAHA.108.790733","volume":"118","author":"Nicholls","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib136","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1194\/jlr.R024075","article-title":"Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk","volume":"53","author":"Barter","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib137","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.jacc.2009.12.067","article-title":"A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome","volume":"55","author":"Waksman","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib138","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib139","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/ATVBAHA.107.148817","article-title":"Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?","volume":"28","author":"Barter","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib141","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2013.08.001_bib142","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1517\/17425255.2011.579561","article-title":"Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk","volume":"7","author":"Younk","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jacl.2013.08.001_bib143","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.jacc.2010.02.035","article-title":"RVX-208: a small molecule\u00a0that increases apolipoprotein A-I and high-density lipoprotein cholesterol in\u00a0vitro and in\u00a0vivo","volume":"55","author":"Bailey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib144","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jacc.2010.11.015","article-title":"Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial","volume":"57","author":"Nicholls","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib145","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10557-012-6373-5","article-title":"ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies","volume":"26","author":"Nicholls","year":"2012","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2013.08.001_bib146","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1194\/jlr.R800088-JLR200","article-title":"Role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis","volume":"50","author":"Rader","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib147","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1161\/01.CIR.0000086981.09834.E0","article-title":"Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in\u00a0vivo","volume":"108","author":"Zhang","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib148","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/ATVBAHA.108.179283","article-title":"Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses","volume":"30","author":"Yvan-Charvet","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib149","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MOL.0b013e3283395e45","article-title":"Transintestinal cholesterol efflux","volume":"21","author":"van der Velde","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2013.08.001_bib150","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-2275(20)43114-1","article-title":"The plasma lecithins:cholesterol acyltransferase reaction","volume":"9","author":"Glomset","year":"1968","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib151","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/MOL.0b013e328338472d","article-title":"High-density lipoprotein heterogeneity and function in reverse cholesterol transport","volume":"21","author":"Rothblat","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2013.08.001_bib152","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1161\/01.RES.0000185320.82962.F7","article-title":"Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation","volume":"97","author":"Moore","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib153","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1172\/JCI25327","article-title":"Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in\u00a0vivo","volume":"115","author":"Zhang","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2013.08.001_bib154","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.105.560177","article-title":"Pharmacological activation of liver X receptors promotes reverse cholesterol transport in\u00a0vivo","volume":"113","author":"Naik","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib155","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/ATVBAHA.111.225383","article-title":"Peroxisome proliferator-activated receptor-alpha activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway","volume":"31","author":"Nakaya","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib156","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/CIRCULATIONAHA.110.009704","article-title":"Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport","volume":"124","author":"Yamamoto","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib157","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/ATVBAHA.109.199158","article-title":"The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages","volume":"30","author":"de la Llera-Moya","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib158","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib159","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/ATVBAHA.109.194548","article-title":"Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent","volume":"29","author":"Larrede","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib160","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.100.6.594","article-title":"Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport in humans","volume":"100","author":"Eriksson","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib161","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1161\/01.ATV.0000161928.16334.dd","article-title":"Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion","volume":"25","author":"Brousseau","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib162","doi-asserted-by":"crossref","first-page":"e001826","DOI":"10.1161\/JAHA.112.001826","article-title":"Measurement of reverse cholesterol transport pathways in humans: in\u00a0vivo rates of free cholesterol efflux, esterification, and excretion","volume":"1","author":"Turner","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2013.08.001_bib163","first-page":"A17881","article-title":"In\u00a0vivo tissue cholesterol efflux is impaired in carriers of mutations in APOA1 and ABCA1","volume":"122","author":"Holleboom","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib164","doi-asserted-by":"crossref","first-page":"A71","DOI":"10.1161\/atvb.32.suppl_1.A71","article-title":"Assessment of reverse cholesterol transport in\u00a0vivo in humans: a novel method","volume":"32","author":"Cuchel","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib165","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-2275(20)39433-5","article-title":"Fate of intravenously administered particulate and lipoprotein cholesterol in the rat","volume":"13","author":"Nilsson","year":"1972","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib166","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.204996","article-title":"Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man","volume":"200","author":"Schwartz","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.jacl.2013.08.001_bib167","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI110683","article-title":"Multicompartmental analysis of cholesterol metabolism in man. Quantitative kinetic evaluation of precursor sources and turnover of high density lipoprotein cholesterol esters","volume":"70","author":"Schwartz","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2013.08.001_bib168","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1172\/JCI116314","article-title":"Cholesterol kinetics in subjects with bile fistula. Positive relationship between size of the bile acid precursor pool and bile acid synthetic rate","volume":"91","author":"Schwartz","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacl.2013.08.001_bib169","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1194\/jlr.M300511-JLR200","article-title":"Lipoprotein cholesteryl ester production, transfer, and output in\u00a0vivo in humans","volume":"45","author":"Schwartz","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib170","series-title":"High-Density Lipoproteins: Structure, Metabolism, Function and Therapeutics","author":"Kontush","year":"2012"},{"key":"10.1016\/j.jacl.2013.08.001_bib171","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1194\/jlr.M700274-JLR200","article-title":"The roles of different pathways in the release of cholesterol from macrophages","volume":"48","author":"Adorni","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib172","doi-asserted-by":"crossref","first-page":"26338","DOI":"10.1074\/jbc.273.41.26338","article-title":"The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain","volume":"273","author":"Gu","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2013.08.001_bib173","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1172\/JCI115532","article-title":"Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein","volume":"88","author":"Navab","year":"1991","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacl.2013.08.001_bib174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0021-9150(95)05675-0","article-title":"High density lipoproteins and coronary heart disease","volume":"121","author":"Barter","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2013.08.001_bib175","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1111\/j.1432-1033.2004.04228.x","article-title":"Apolipoproteins A-I and A-II are potentially important effectors of innate immunity in the teleost fish Cyprinus carpio","volume":"271","author":"Concha","year":"2004","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.jacl.2013.08.001_bib176","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.fsi.2006.10.008","article-title":"Apolipoprotein A-I, an antimicrobial protein in Oncorhynchus mykiss: evaluation of its expression in primary defence barriers and plasma levels in sick and healthy fish","volume":"23","author":"Villarroel","year":"2007","journal-title":"Fish Shellfish Immunol"},{"key":"10.1016\/j.jacl.2013.08.001_bib177","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cbpb.2008.06.011","article-title":"Apolipoprotein A-I from striped bass (Morone saxatilis) demonstrates antibacterial activity in\u00a0vitro","volume":"151","author":"Johnston","year":"2008","journal-title":"Comp Biochem Physiol B Biochem Mol Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib178","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0928-8244(03)00125-1","article-title":"Serum high-density lipoprotein (HDL) inhibits in\u00a0vitro enterohemolysin (EHly) activity produced by enteropathogenic Escherichia coli","volume":"38","author":"Figueiredo","year":"2003","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib179","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0022-2275(20)33363-0","article-title":"Lipoproteins inhibit macrophage activation by lipoteichoic acid","volume":"40","author":"Grunfeld","year":"1999","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib180","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/abbs\/36.6.419","article-title":"Role of apolipoprotein A-I in protecting against endotoxin toxicity","volume":"36","author":"Ma","year":"2004","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1016\/j.jacl.2013.08.001_bib181","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1128\/IAI.63.1.253-258.1995","article-title":"Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood","volume":"63","author":"Parker","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.jacl.2013.08.001_bib182","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cyto.2008.04.002","article-title":"Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid","volume":"43","author":"Jiao","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.jacl.2013.08.001_bib183","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ejphar.2008.06.047","article-title":"Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice","volume":"590","author":"Li","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jacl.2013.08.001_bib184","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1440-1681.2010.05377.x","article-title":"High-density lipoproteins, platelets and the pathogenesis of atherosclerosis","volume":"37","author":"Nofer","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib185","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/MED.0b013e328337278b","article-title":"High-density lipoprotein and the acute phase response","volume":"17","author":"Jahangiri","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jacl.2013.08.001_bib186","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tem.2010.10.001","article-title":"High density lipoprotein: it's not just about lipid transport anymore","volume":"22","author":"Gordon","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jacl.2013.08.001_bib187","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/pmic.200401010","article-title":"Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry","volume":"5","author":"Karlsson","year":"2005","journal-title":"Proteomics"},{"key":"10.1016\/j.jacl.2013.08.001_bib188","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1002\/pmic.200401233","article-title":"Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins","volume":"5","author":"Heller","year":"2005","journal-title":"Proteomics"},{"key":"10.1016\/j.jacl.2013.08.001_bib189","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.bbrc.2005.12.098","article-title":"Diverse range of small peptides associated with high-density lipoprotein","volume":"340","author":"Hortin","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacl.2013.08.001_bib190","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/pmic.200500191","article-title":"Proteomic analysis of high-density lipoprotein","volume":"6","author":"Rezaee","year":"2006","journal-title":"Proteomics"},{"key":"10.1016\/j.jacl.2013.08.001_bib191","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1172\/JCI26206","article-title":"Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL","volume":"117","author":"Vaisar","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2013.08.001_bib192","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/ATVBAHA.109.186031","article-title":"Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function","volume":"29","author":"Davidson","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib193","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.bbalip.2011.07.013","article-title":"The HDL proteome in acute coronary syndromes shifts to an inflammatory profile","volume":"1821","author":"Alwaili","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacl.2013.08.001_bib194","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1194\/jlr.M027367","article-title":"Psoriasis alters HDL composition and cholesterol efflux capacity","volume":"53","author":"Holzer","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib195","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2010111144","article-title":"Uremia alters HDL composition and function","volume":"22","author":"Holzer","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2013.08.001_bib196","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1681\/ASN.2011070668","article-title":"Serum amyloid A in uremic HDL promotes inflammation","volume":"23","author":"Weichhart","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2013.08.001_bib197","doi-asserted-by":"crossref","first-page":"e34107","DOI":"10.1371\/journal.pone.0034107","article-title":"HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approach","volume":"7","author":"Mange","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.jacl.2013.08.001_bib198","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/art.34363","article-title":"Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis","volume":"64","author":"Watanabe","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jacl.2013.08.001_bib199","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1021\/pr100520x","article-title":"Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography","volume":"9","author":"Gordon","year":"2010","journal-title":"J Proteome Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib200","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1194\/jlr.R035725","article-title":"The proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond","volume":"54","author":"Shah","year":"2013","journal-title":"J Lipid Res."},{"key":"10.1016\/j.jacl.2013.08.001_bib201","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1194\/jlr.M700362-JLR200","article-title":"Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency","volume":"49","author":"Santos","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib202","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1073\/pnas.75.7.3450","article-title":"Identification of the trypanocidal factor in normal human serum: high density lipoprotein","volume":"75","author":"Rifkin","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2013.08.001_bib203","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.111.000232","article-title":"Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease","volume":"1","author":"Jensen","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2013.08.001_bib204","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/pmic.200300938","article-title":"Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry","volume":"5","author":"Karlsson","year":"2005","journal-title":"Proteomics"},{"key":"10.1016\/j.jacl.2013.08.001_bib205","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/prca.200800138","article-title":"Protein profiling of low-density lipoprotein from obese subjects","volume":"3","author":"Karlsson","year":"2009","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.jacl.2013.08.001_bib206","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1194\/jlr.D700025-JLR200","article-title":"Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O\/sucrose or in KBr","volume":"49","author":"Stahlman","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib207","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/pmic.200600339","article-title":"Proteomic analysis of human very low-density lipoprotein by two-dimensional gel electrophoresis and MALDI-TOF\/TOF","volume":"7","author":"Mancone","year":"2007","journal-title":"Proteomics"},{"key":"10.1016\/j.jacl.2013.08.001_bib208","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.cca.2010.03.023","article-title":"HDL in humans with cardiovascular disease exhibits a proteomic signature","volume":"411","author":"Vaisar","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jacl.2013.08.001_bib209","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1161\/CIRCULATIONAHA.108.770669","article-title":"Combined statin and niacin therapy remodels the high-density lipoprotein proteome","volume":"118","author":"Green","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib210","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.steroids.2012.01.002","article-title":"Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men","volume":"77","author":"Rubinow","year":"2012","journal-title":"Steroids"},{"key":"10.1016\/j.jacl.2013.08.001_bib211","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1194\/jlr.P026005","article-title":"Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity","volume":"53","author":"Rubinow","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib212","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1194\/jlr.D800028-JLR200","article-title":"Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry","volume":"50","author":"Wiesner","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib213","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1194\/jlr.M006494","article-title":"Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol","volume":"51","author":"Yetukuri","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib214","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1194\/jlr.M009449","article-title":"Lipidomics reveals a remarkable diversity of lipids in human plasma","volume":"51","author":"Quehenberger","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib215","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/ATVBAHA.107.145672","article-title":"Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities","volume":"27","author":"Kontush","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib216","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbalip.2010.11.003","article-title":"Sphingolipid profiling of human plasma and FPLC-separated lipoprotein fractions by hydrophilic interaction chromatography tandem mass spectrometry","volume":"1811","author":"Scherer","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacl.2013.08.001_bib217","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.chroma.2010.01.006","article-title":"Profiling of phospholipids in lipoproteins by multiplexed hollow fiber flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry","volume":"1217","author":"Lee","year":"2010","journal-title":"J\u00a0Chromatogr A"},{"key":"10.1016\/j.jacl.2013.08.001_bib218","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1073\/pnas.97.4.1743","article-title":"Cardiolipin is a normal component of human plasma lipoproteins","volume":"97","author":"Deguchi","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2013.08.001_bib219","doi-asserted-by":"crossref","first-page":"8959","DOI":"10.1016\/S0021-9258(17)37061-8","article-title":"The molecular basis for the difference in charge between pre-beta- and alpha-migrating high density lipoproteins","volume":"269","author":"Davidson","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2013.08.001_bib220","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1139\/O07-137","article-title":"Lipoprotein electrostatic properties regulate hepatic lipase association and activity","volume":"85","author":"Boucher","year":"2007","journal-title":"Biochem Cell Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib221","doi-asserted-by":"crossref","first-page":"10316","DOI":"10.1073\/pnas.89.21.10316","article-title":"High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors","volume":"89","author":"Bowry","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2013.08.001_bib222","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1074\/jbc.273.11.6080","article-title":"Oxidation of high density lipoproteins, I: formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol","volume":"273","author":"Garner","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2013.08.001_bib223","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/01.ATV.17.4.786","article-title":"Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis","volume":"17","author":"Goulinet","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib224","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1042\/bj1040340","article-title":"Lipid composition of human serum lipoproteins","volume":"104","author":"Skipski","year":"1967","journal-title":"Biochem J"},{"key":"10.1016\/j.jacl.2013.08.001_bib225","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-2275(20)36996-0","article-title":"Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias","volume":"17","author":"Dawson","year":"1976","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib226","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1432-1033.1989.tb14773.x","article-title":"Gangliosides in normal human serum. Concentration, pattern and transport by lipoproteins","volume":"181","author":"Senn","year":"1989","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.jacl.2013.08.001_bib227","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1365-2362.1999.00438.x","article-title":"Distribution of diacylglycerols among plasma lipoproteins in control subjects and in patients with non-insulin-dependent diabetes","volume":"29","author":"Lalanne","year":"1999","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacl.2013.08.001_bib228","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.tcm.2005.08.005","article-title":"Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids","volume":"15","author":"Nofer","year":"2005","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib229","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1194\/jlr.M500357-JLR200","article-title":"Absorption and lipoprotein transport of sphingomyelin","volume":"47","author":"Nilsson","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib230","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/01.ATV.0000091338.93223.E8","article-title":"Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress","volume":"23","author":"Kontush","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib231","doi-asserted-by":"crossref","first-page":"14811","DOI":"10.1021\/bi0485629","article-title":"Molecular mechanism of reverse cholesterol transport: reaction of pre-beta-migrating high-density lipoprotein with plasma lecithin\/cholesterol acyltransferase","volume":"43","author":"Nakamura","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.jacl.2013.08.001_bib232","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1582-4934.2009.00713.x","article-title":"Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I","volume":"14","author":"de Souza","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib233","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.atherosclerosis.2007.08.009","article-title":"Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity","volume":"197","author":"de Souza","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2013.08.001_bib234","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1073\/pnas.1103187108","article-title":"Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M","volume":"108","author":"Christoffersen","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2013.08.001_bib235","doi-asserted-by":"crossref","first-page":"36596","DOI":"10.1074\/jbc.M006924200","article-title":"High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI","volume":"275","author":"Yancey","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2013.08.001_bib236","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1074\/jbc.270.11.5882","article-title":"The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular free cholesterol","volume":"270","author":"Davidson","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2013.08.001_bib237","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1021\/bi00216a001","article-title":"Packing characteristics of highly unsaturated bilayer lipids: Raman spectroscopic studies of multilamellar phosphatidylcholine dispersions","volume":"30","author":"Litman","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.jacl.2013.08.001_bib238","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1161\/ATVBAHA.109.194555","article-title":"HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis","volume":"29","author":"Zerrad-Saadi","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib239","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1161\/ATVBAHA.107.161042","article-title":"HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production","volume":"28","author":"Tolle","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib240","doi-asserted-by":"crossref","first-page":"10627","DOI":"10.1074\/jbc.M011449200","article-title":"Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production","volume":"276","author":"Kwon","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2013.08.001_bib241","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1161\/01.RES.0000225982.01988.93","article-title":"Endothelial and antithrombotic actions of HDL","volume":"98","author":"Mineo","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib242","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI200418004","article-title":"HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3","volume":"113","author":"Nofer","year":"2004","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacl.2013.08.001_bib243","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbalip.2008.06.008","article-title":"S1P and eNOS regulation","volume":"1781","author":"Igarashi","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacl.2013.08.001_bib244","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.atherosclerosis.2006.10.020","article-title":"Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation","volume":"194","author":"Matsuo","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2013.08.001_bib245","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/CIRCRESAHA.111.258673","article-title":"Novel biological functions of high-density lipoprotein cholesterol","volume":"111","author":"Mineo","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib246","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncb2210","article-title":"MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins","volume":"13","author":"Vickers","year":"2011","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib247","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/pr.58.3.1","article-title":"Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis","volume":"58","author":"Kontush","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jacl.2013.08.001_bib248","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1194\/jlr.M018010","article-title":"Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib","volume":"53","author":"Krauss","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib249","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1194\/jlr.M016410","article-title":"Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters","volume":"52","author":"Castro-Perez","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib250","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJM198911093211907","article-title":"High-density lipoprotein\u2013the clinical implications of recent studies","volume":"321","author":"Gordon","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib251","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.ATV.8.6.737","article-title":"High density lipoprotein cholesterol and mortality. The Framingham Heart Study","volume":"8","author":"Wilson","year":"1988","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.jacl.2013.08.001_bib252","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1172\/JCI0216391","article-title":"Regulation and mechanisms of macrophage cholesterol efflux","volume":"110","author":"Tall","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2013.08.001_bib253","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/jama.299.21.2524","article-title":"Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease","volume":"299","author":"Frikke-Schmidt","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.08.001_bib254","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1161\/01.ATV.0000083343.19940.A0","article-title":"Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells","volume":"23","author":"Covey","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2013.08.001_bib255","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.RES.0000146094.59640.13","article-title":"Antiinflammatory properties of HDL","volume":"95","author":"Barter","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib256","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1161\/01.CIR.0000013424.28206.8F","article-title":"High-density lipoprotein restores endothelial function in hypercholesterolemic men","volume":"105","author":"Spieker","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib257","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1194\/jlr.M600370-JLR200","article-title":"Inflammation and skin cholesterol in LDLr-\/-, apoA-I-\/- mice: link between cholesterol homeostasis and self-tolerance?","volume":"48","author":"Zabalawi","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib258","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1194\/jlr.R400001-JLR200","article-title":"The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL","volume":"45","author":"Navab","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib259","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2013an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib260","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/bmj.321.7255.199","article-title":"Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses","volume":"321","author":"Danesh","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2013.08.001_bib261","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","article-title":"Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.08.001_bib262","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI118345","article-title":"Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures","volume":"96","author":"Van Lenten","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2013.08.001_bib263","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nm0797-744","article-title":"High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase","volume":"3","author":"Berard","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.jacl.2013.08.001_bib264","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1021\/tx9003775","article-title":"Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein","volume":"23","author":"Shao","year":"2010","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.jacl.2013.08.001_bib265","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0022-2275(20)39863-1","article-title":"Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux","volume":"36","author":"Banka","year":"1995","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2013.08.001_bib266","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacl.2011.06.012","article-title":"The surprising AIM-HIGH results are not surprising when viewed through a particle lens","volume":"5","author":"Otvos","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2013.08.001_bib267","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jacc.2012.03.060","article-title":"High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"60","author":"Mackey","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2013.08.001_bib268","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0002-8703(92)90288-7","article-title":"Efficacy of lipid profiles in prediction of coronary disease","volume":"124","author":"Kannel","year":"1992","journal-title":"Am Heart J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287413002493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287413002493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T10:40:29Z","timestamp":1715856029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287413002493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":268,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1933287413002493"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2013.08.001","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}